HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Panteghini, M. Search for Related Content PubMed PubMed Citation Articles by Panteghini, M. Related Collections Proteomics and Protein Markers

Selection of Antibodies and Epitopes for Cardiac Troponin Immunoassays: Should We Revise Our Evidence-Based Beliefs?

Cattedra di Biochimica Clinica e Biologia Molecolare Clinica, Dipartimento di Scienze Cliniche "Luigi Sacco", Facoltà di Medicina e Chirurgia-Polo di Vialba, Università degli Studi di Milano, Via G.B. Grassi 74, 20157 Milan, Italy, Fax 39-02-38201626, E-mail mauro.panteghini@unimi.it

The first 20% of the full text of this article appears below.

Cardiac troponins are regarded as the most specific and sensitive of the currently available diagnostic techniques for detection of myocardial damage, and the redefined criteria used to classify acute coronary syndrome patients presenting with ischemic symptoms as myocardial infarction patients are heavily predicated on an increased concentration of these markers in blood (1). Troponins also are the only markers identifying high-risk coronary patients who should be treated with antithrombotic agents, such as glycoprotein IIb/IIIa antagonists, and referred for invasive evaluation at the earliest opportunity. Not all troponin assays, however, are created equal; therefore, method selection by the clinical laboratory represents one of the major factors influencing the performance of this important biomarker for the diagnostic classification of an individual patient. Recent experimental data indicated that various commercially available methods have different limits of detection (and imprecision) for cardiac troponins (2). Thus, the percentage of patients recategorized from angina to myocardial infarction based on troponin results as a diagnostic criterion is also critically dependent on the performance of the assay used (3).

Formulation of assay reagents is also important in minimizing analytic interference. Falsely increased or decreased troponin results may occur because of interferences with the antigen–antibody reaction. Interferences from rheumatoid factors or human anti-mouse antibodies, which can mimic troponin by linking the capture and detector antibodies, have been reported (4). Icteric and hemolyzed serum samples might also be a problem in certain immunoassays (5). Finally, an interfering blood component inhibiting the binding of some antibodies against epitopes in the central part . . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				P. Unverir, B. C. Soner, E. Dedeoglu, O. Karcioglu, K. Boztok, and Y. Tuncok Renal and hepatic injury with elevated cardiac enzymes in Amanita phalloides poisoning: a case report Human and Experimental Toxicology, September 1, 2007; 26(9): 757 - 761. [Abstract] [PDF]

				A. H.B. Wu Cardiac Troponin: Friend of the Cardiac Physician, Foe to the Cardiac Patient? Circulation, October 17, 2006; 114(16): 1673 - 1675. [Full Text] [PDF]

				M. Panteghini Standardization of Cardiac Troponin I Measurements: The Way Forward? Clin. Chem., September 1, 2005; 51(9): 1594 - 1597. [Full Text] [PDF]

				S. Eriksson and K. Pettersson Beliefs in Cardiac Troponin Testing Clin. Chem., September 1, 2005; 51(9): 1755 - 1756. [Full Text] [PDF]

eLetters: